<DOC>
	<DOCNO>NCT01208441</DOCNO>
	<brief_summary>This phase I trial study side effect best dose RO4929097 give together letrozole treat post-menopausal woman stage II stage III breast cancer . RO4929097 may stop growth tumor cell block enzymes need cell growth . Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer block use estrogen tumor cell . Giving RO4929097 together letrozole may effective treatment breast cancer .</brief_summary>
	<brief_title>RO4929097 Letrozole Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish maximum-tolerated dose recommend phase II dose gamma-secretase inhibitor RO4929097 ( RO4929097 ) combination letrozole post-menopausal woman hormone receptor-positive stage II III breast cancer . II . To assess safety regimen patient . SECONDARY OBJECTIVES : I . To evaluate pharmacokinetics regimen , take consideration induction CYP3A4 , patient . II . To characterize pharmacodynamic effect letrozole prior administration RO4929097 attention suppression estradiol estrone level . III . To describe pharmacodynamic effect letrozole without RO4929097 NOTCH pathway , proliferation , angiogenesis , stromal cell infiltration/pathways , comprehensive genomic analysis tumor tissue patient . IV . To describe response , include clinical complete partial objective response , pathological complete response , attainment pathologic stage 0 I status patient . OUTLINE : This multicenter , dose-escalation study gamma-secretase inhibitor RO4929097 ( RO4929097 ) . Patients receive oral letrozole daily day 1-21 . Beginning course 2 , patient also receive oral RO4929097 day 1-3 , 8-10 , 15-18 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Beginning 1 week completion neoadjuvant therapy , patient undergo surgery tumor biopsy . Patients continue receive oral letrozole daily surgery additional 4 week . Blood tumor tissue sample collect baseline periodically study pharmacokinetics , pharmacodynamics , correlative study . After completion study therapy , patient follow 1 month every 6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Pathologically confirm invasive breast cancer Stage II III disease ( T2T3 , N02 ) No N3 , T4 disease Estrogen receptorpositive ( ER+ ) and/or progesterone receptorpositive ( PR+ ) H score ≥ 10 positivity ≥ 10 % HER2 negative determine IHC ( 1 2+ ) FISH ( &lt; 2.0+ ) Bilateral disease allow long tumor ER+ ≥ 1 T2T3 Patient must disease palpable physical exam able imaged via breast ultrasound Defined ≥ 1 T2 tumor &gt; 2 cm Multifocal disease allow provide ≥ 1 tumor &gt; 2 cm No metastatic disease CT scan chest , abdomen , pelvis , PET/CT bone scan , nuclear medicine bone scan No inflammatory breast cancer presence breast tumor cell dermal lymphatics breast Postmenopausal meet 1 follow criterion : Bilateral oophorectomy Age ≥ 50 year amenorrheic &gt; 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression ( spontaneous amenorrhea ) ECOG performance status ( PS ) 02 ( Karnofsky PS 60100 % ) Life expectancy &gt; 3 month ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Baseline QTcF ≤ 470 msec No history allergic reaction attribute compound similar chemical biologic composition gamma secretase inhibitor RO4929097 agent use study No malabsorption syndrome condition would interfere intestinal absorption Able swallow tablet Not serologically positive hepatitis A , B , C , history liver disease , form hepatitis , cirrhosis No uncontrolled electrolyte abnormality include hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia , hypokalemia despite adequate electrolyte supplementation No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris History torsades de pointes significant cardiac arrhythmia chronic , stable atrial fibrillation Psychiatric illness and/or social situation would limit compliance study requirement Recovered &lt; grade 2 CTCAE toxicity relate prior therapy No prior chemotherapy , hormonal therapy , radiotherapy , biological therapy breast cancer Prior treatment nonmelanoma skin cancer carcinoma situ cervix allow No prior hormone therapy ductal carcinoma situ ( DCIS ) No concurrent investigational agent No concurrent medication narrow therapeutic index metabolize cytochrome P450 ( CYP450 ) , include warfarin sodium ( Coumadin® ) No concurrent medication strong inducer and/or inhibitor substrates CYP3A4 Switching alternative medication allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent antiarrhythmic medication know prolong QTc No concurrent anticancer agent therapies No concurrent grapefruit juice</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>